What are the right ingredients for a blockbuster unicorn IPO? Norbert Bischofberger has some thoughts on that
2020 will stand out in the history of biotech for a variety of reasons, starting with the unprecedented, rapid-fire response to Covid-19. But somewhere in the top 5 there will be a special spotlight on the IPO boom, which has been funneling billions of dollars into drug development and offering some key players a shot at rock star status — and rock star money.
Premium subscription required
Unlock this article along with other benefits by subscribing to one of our paid plans.